Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
OTL-203 by Orchard Therapeutics for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ): Likelihood of Approval
OTL-203 is under clinical development by Orchard Therapeutics and currently in Phase III for Mucopolysaccharidosis I (MPS I) (Hurler Syndrome...